Anguille Sébastien, Lion Eva, Van den Bergh Johan, Van Acker Heleen H, Willemen Yannick, Smits Evelien L, Van Tendeloo Viggo F, Berneman Zwi N
Vaccine & Infectious Disease Institute; Laboratory of Experimental Hematology; Tumor Immunology Group (TIGR); University of Antwerp; Antwerp, Belgium; Center for Cell Therapy & Regenerative Medicine; Antwerp University Hospital; Antwerp, Belgium.
Hum Vaccin Immunother. 2013 Sep;9(9):1956-61. doi: 10.4161/hv.25373. Epub 2013 Jun 18.
Owing to their professional antigen-presenting capacity and unique potential to induce tumor antigen-specific T cell immunity, dendritic cells (DCs) have attracted much interest over the past decades for therapeutic vaccination against cancer. Clinical trials have shown that the use of tumor antigen-loaded DCs in cancer patients is safe and that it has the potential to induce anti-tumor immunity which, in some cases, culminates in striking clinical responses. Unfortunately, in a considerable number of patients, DC vaccination is unable to mount effective anti-tumor immune responses and, if it does so, the resultant immunity is often insufficient to translate into tangible clinical benefit. This underscores the necessity to re-design and optimize the current procedures for DC vaccine manufacturing. A new generation of DC vaccines with improved potency has now become available for clinical use as a result of extensive pre-clinical research. One of the promising next-generation DC vaccine candidates are interleukin (IL)-15-differentiated DCs. In this commentary, we will compile the research data that have been obtained by our group and other groups with these so-called IL-15 DCs and summarize the evidence supporting the implementation of IL-15 DCs in DC-based cancer vaccination regimens.
由于其专业的抗原呈递能力以及诱导肿瘤抗原特异性T细胞免疫的独特潜力，在过去几十年中，树突状细胞（DC）在癌症治疗性疫苗接种方面引起了广泛关注。临床试验表明，在癌症患者中使用负载肿瘤抗原的DC是安全的，并且有潜力诱导抗肿瘤免疫，在某些情况下，这种免疫反应最终会带来显著的临床反应。不幸的是，在相当数量的患者中，DC疫苗接种无法引发有效的抗肿瘤免疫反应，即使能够引发，产生的免疫反应往往也不足以转化为切实的临床益处。这凸显了重新设计和优化当前DC疫苗生产程序的必要性。经过广泛的临床前研究，新一代效力增强的DC疫苗现已可供临床使用。有前景的下一代DC疫苗候选之一是白细胞介素（IL）-15分化的DC。在这篇评论中，我们将汇总我们团队和其他团队通过这些所谓的IL-15 DC获得的研究数据，并总结支持在基于DC的癌症疫苗接种方案中应用IL-15 DC的证据。
